Yan Wu
C Ray Therapeutics (Chengdu) Co., Ltd. · Peking University First Hospital · Chief Medical Officer
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yan Wu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:58 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07567521 · A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPCC Ray Therapeutics · recruiting · Prostate Cancer · study director
- Ph1NCT07236112 · Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate CancerC Ray Therapeutics · active not recruiting · Prostate Cancer · study chair
- Ph3NCT06585696 · A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)Cutia Therapeutics(Wuxi)Co.,Ltd · completed · Glabellar Frown Lines · principal investigator
- Ph3NCT06583486 · A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar LinesChongqing Claruvis Pharmaceutical Co., Ltd. · completed · Moderate to Severe Glabellar Lines · principal investigator
- Ph3NCT06499688 · A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar LinesChongqing Claruvis Pharmaceutical Co., Ltd. · completed · Moderate to Severe Glabellar Lines · principal investigator
- Ph3NCT05463965 · A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar LinesGalderma R&D · completed · Moderate to Severe Glabellar Lines · principal investigator
- Ph1/Ph2NCT05434897 · A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic ScarShanghai Ark Biopharmaceutical Co., Ltd. · completed · Hypertrophic Scar · study chair
- Ph2NCT05424887 · A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary FibrosisShanghai Ark Biopharmaceutical Co., Ltd. · unknown · Idiopathic Pulmonary Fibrosis · study chair
- N/ANCT05009381 · Effectiveness and Safety of STYLAGE® XXL for Chin Augmentation in Chinese AdultsLaboratoires Vivacy · completed · Esthetic · principal investigator
- N/ANCT04861766 · Safety and Effectiveness of STYLAGE® L for Correction of Moderate and Severe Nasolabial Folds in Chinese AdultsLaboratoires Vivacy · completed · Aging, Skin Wrinkling · principal investigator
- N/ANCT02705014 · Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption SyndromePeking Union Medical College Hospital · unknown · Hypogonadotropic Hypogonadism · principal investigator
- Ph1NCT02105129 · A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523Hutchison Medipharma Limited · completed · Rheumatoid Arthritis (RA) · study director
- N/ANCT01281605 · Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 DiabetesMackay Memorial Hospital · completed · Type 2 Diabetes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 21 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:58 UTC. The ranking covers the 200 most relevant of 2382 PubMed records, and a shared surname and initials can bring in a namesake. All 2382 on PubMed
- Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.J Clin Oncol · 2024362 citationsRCR 44.1
- Middle Meningeal Artery Embolization for Nonacute Subdural Hematoma.N Engl J Med · 2024220 citationsRCR 62.0
- 169 citationsRCR 16.1
- 144 citationsRCR 23.7
- 131 citationsRCR 14.5
- Inebilizumab for Treatment of IgG4-Related Disease.N Engl J Med · 2025131 citationsRCR 39.3
- Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.N Engl J Med · 2025100 citationsRCR 18.5
- 85 citationsRCR 14.4
- 82 citationsRCR 27.2
- Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.Nat Med · 202576 citationsRCR 15.0